

# Siddhartha Ganguly

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9536768/publications.pdf>

Version: 2024-02-01

108  
papers

2,340  
citations

304743

22  
h-index

233421

45  
g-index

108  
all docs

108  
docs citations

108  
times ranked

3333  
citing authors

#	ARTICLE	IF	CITATIONS
1	Functional characterization of NPM1-TYK2 fusion oncogene. <i>Npj Precision Oncology</i> , 2022, 6, 3.	5.4	2
2	Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 187.e1-187.e10.	1.2	3
3	Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 581.e1-581.e8.	1.2	61
4	Clinical Outcomes in Patients with FLT3-ITD-Mutated Relapsed/Refractory Acute Myelogenous Leukemia Undergoing Hematopoietic Stem Cell Transplantation after Quizartinib or Salvage Chemotherapy in the QuANTUM-R Trial. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 153-162.	1.2	16
5	Outcomes of Daratumumab, Pomalidomide, and Dexamethasone, Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation, in Patients With Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e212-e219.	0.4	3
6	Peri-transplant extracorporeal photopheresis to mitigate GVHD- a pilot clinical trial. <i>Bone Marrow Transplantation</i> , 2021, 56, 980-982.	2.4	3
7	Outcomes of VD-PACE With Immunomodulatory Agent as a Salvage Therapy for Relapsed/Refractory Multiple Myeloma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2021, 21, e220-e226.	0.4	8
8	High-level MYC expression associates with poor survival in patients with acute myeloid leukemia and collaborates with overexpressed p53 in leukemic transformation in patients with myelodysplastic syndrome. <i>International Journal of Laboratory Hematology</i> , 2021, 43, 99-109.	1.3	7
9	Preclinical Evaluation of Gilteritinib on NPM1-ALK-Driven Anaplastic Large Cell Lymphoma Cells. <i>Molecular Cancer Research</i> , 2021, 19, 913-920.	3.4	5
10	Telehealth to increase access to transplant survivorship care for allogeneic stem cell transplant recipients regardless of distance to transplant center or neighborhood income.. <i>Journal of Clinical Oncology</i> , 2021, 39, e13615-e13615.	1.6	2
11	Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).. <i>Journal of Clinical Oncology</i> , 2021, 39, 7552-7552.	1.6	5
12	Acute polymyositis presenting as chronic graft-versus-host disease: A systemic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, e19025-e19025.	1.6	0
13	Gender disparities in National Institute of Health funding for hematologic malignancies, hematopoietic stem cell transplantation, and cellular therapeutics.. <i>Journal of Clinical Oncology</i> , 2021, 39, 11020-11020.	1.6	0
14	Carfilzomib, cyclophosphamide, and dexamethasone (KCd) for the treatment of triple-class relapsed/refractory multiple myeloma (RRMM). <i>European Journal of Haematology</i> , 2021, 107, 602-608.	2.2	7
15	Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 796.e1-796.e7.	1.2	42
16	Novel prognostic scoring system for autologous hematopoietic cell transplantation in multiple myeloma. <i>British Journal of Haematology</i> , 2020, 191, 442-452.	2.5	8
17	Health Care Reimbursement, Service Utilization, and Outcomes among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 805-813.	2.0	7
18	A Phase I Study to Evaluate Two Doses of Wharton's Jelly-Derived Mesenchymal Stromal Cells for the Treatment of De Novo High-Risk or Steroid-Refractory Acute Graft Versus Host Disease. <i>Stem Cell Reviews and Reports</i> , 2020, 16, 979-991.	3.8	23

#	ARTICLE	IF	CITATIONS
19	Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation. <i>Leukemia Research</i> , 2020, 95, 106402.	0.8	13
20	Orvacabtagene autoleucl (orva-cel), a B-cell maturation antigen (BCMA)-directed CAR T cell therapy for patients (pts) with relapsed/refractory multiple myeloma (RRMM): update of the phase 1/2 EVOLVE study (NCT03430011).. <i>Journal of Clinical Oncology</i> , 2020, 38, 8504-8504.	1.6	89
21	Autologous hematopoietic stem cell transplant is safe for elderly lymphoma patients. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2019, 12, 124-125.	0.9	1
22	The Concentration of Total Nucleated Cells in Harvested Bone Marrow for Transplantation Has Decreased over Time. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1325-1330.	2.0	13
23	Virus detection in the cerebrospinal fluid of hematopoietic stem cell transplant recipients is associated with poor patient outcomes: a CIBMTR contemporary longitudinal study. <i>Bone Marrow Transplantation</i> , 2019, 54, 1354-1360.	2.4	19
24	Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 984-997.	10.7	330
25	Results of the First Clinical Study in Humans That Combines Hyperbaric Oxygen Pretreatment with Autologous Peripheral Blood Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1713-1719.	2.0	7
26	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. <i>Pharmaceutical Research</i> , 2019, 36, 93.	3.5	4
27	Autologous Hematopoietic Stem Cell Transplantation for Male Germ Cell Tumors: Improved Outcomes Over 3 Decades. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1099-1106.	2.0	12
28	CDC37 as a novel target for the treatment of NPM1-ALK expressing anaplastic large cell lymphomas. <i>Blood Cancer Journal</i> , 2019, 9, 14.	6.2	3
29	Revised International Staging System Is Predictive and Prognostic for Early Relapse (<24 months) after Autologous Transplantation for Newly Diagnosed Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 683-688.	2.0	18
30	Effect of Conditioning Regimen Dose Reduction in Obese Patients Undergoing Autologous Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 480-487.	2.0	10
31	Epstein-Barr viremia and post-transplant lymphoproliferative disorders in patients undergoing haploidentical stem cell transplantation with post-transplant cyclophosphamide. <i>Hematology/Oncology and Stem Cell Therapy</i> , 2019, 12, 171-173.	0.9	7
32	Targeted Therapy for EBV-Associated B-cell Neoplasms. <i>Molecular Cancer Research</i> , 2019, 17, 839-844.	3.4	7
33	Non-Graft-versus-Host Disease Ocular Complications after Hematopoietic Cell Transplantation: Expert Review from the Late Effects and Quality of Life Working Committee of the Center for International Blood and Marrow Transplant Research and the Transplant Complications Working Party of the European Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, e145-e154.	2.0	16
34	Characteristics of Late Fatal Infections after Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 362-368.	2.0	40
35	Effect of Co-Mutations and FLT3-ITD Variant Allele Frequency (VAF) on Response to Quizartinib or Salvage Chemotherapy (SC) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML). <i>Blood</i> , 2019, 134, 737-737.	1.4	3
36	Characterization of Response and Transfusion Independence in Patients with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory Acute Myeloid Leukemia Treated with Quizartinib or Salvage Chemotherapy in the Quantum-R Trial. <i>Blood</i> , 2019, 134, 2599-2599.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Clinical Outcomes and Characteristics of Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Undergoing Hematopoietic Stem Cell Transplant (HSCT) after Quizartinib (Q) or Salvage Chemotherapy (SC) in the Quantum-R Trial. <i>Blood</i> , 2019, 134, 736-736.	1.4	6
38	Voxtalisis (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial. <i>Lancet Haematology</i> , 2018, 5, e170-e180.	4.6	44
39	Autologous transplantation versus allogeneic transplantation in patients with follicular lymphoma experiencing early treatment failure. <i>Cancer</i> , 2018, 124, 2541-2551.	4.1	61
40	Utility of routine surveillance imaging for diffuse large B-cell lymphoma post autologous transplant: A single center experience. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 135-141.	0.9	1
41	Country-Level Macroeconomic Indicators Predict Early Post-Allogeneic Hematopoietic Cell Transplantation Survival in Acute Lymphoblastic Leukemia: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1928-1935.	2.0	2
42	Autologous/Allogeneic Hematopoietic Cell Transplantation versus Tandem Autologous Transplantation for Multiple Myeloma: Comparison of Long-Term Postrelapse Survival. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 478-485.	2.0	31
43	Assessment of Impact of HLA Type on Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Chronic Lymphocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 581-586.	2.0	5
44	Donor Experiences of Second Marrow or Peripheral Blood Stem Cell Collection Mirror the First, but CD34+ Yields Are Less. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 175-184.	2.0	7
45	Autologous Transplantation in Follicular Lymphoma with Early Therapy Failure: A National LymphoCare Study and Center for International Blood and Marrow Transplant Research Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 1163-1171.	2.0	105
46	Efficacy of High-Dose Therapy and Autologous Hematopoietic Cell Transplantation in Gray Zone Lymphoma: A US Multicenter Collaborative Study. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 486-493.	2.0	3
47	Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia. <i>Blood Advances</i> , 2018, 2, 2922-2936.	5.2	35
48	Retrospective evaluation of fidaxomicin versus oral vancomycin for treatment of <i>Clostridium difficile</i> infections in allogeneic stem cell transplant. <i>Hematology/ Oncology and Stem Cell Therapy</i> , 2018, 11, 233-240.	0.9	12
49	Clinical characteristics and treatment outcome of patients with isochromosome 17q (i17q) abnormality and myeloid neoplasms: A single center experience. <i>Leukemia Research Reports</i> , 2018, 10, 55-56.	0.4	3
50	Risk of acute myeloid leukemia and myelodysplastic syndrome after autotransplants for lymphomas and plasma cell myeloma. <i>Leukemia Research</i> , 2018, 74, 130-136.	0.8	47
51	Staging Systems for Newly Diagnosed Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplantation: The Revised International Staging System Shows the Most Differentiation between Groups. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2443-2449.	2.0	11
52	Efficacy and Safety of Single-Agent Quizartinib (Q), a Potent and Selective FLT3 Inhibitor (FLT3i), in Patients (pts) with FLT3-Internal Tandem Duplication (FLT3-ITD)-Mutated Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) Enrolled in the Global, Phase 3, Randomized Controlled Quantum-R Trial. <i>Blood</i> , 2018, 132, 563-563.	1.4	26
53	Immune Profiling of Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide and Low-Dose Dexamethasone in Combination with Daratumumab. <i>Blood</i> , 2018, 132, 2012-2012.	1.4	3
54	Daratumumab, Pomalidomide, and Dexamethasone (DPd) for the Treatment of Relapsed/Refractory Multiple Myeloma: A Single Institution Experience. <i>Blood</i> , 2018, 132, 5642-5642.	1.4	3

#	ARTICLE	IF	CITATIONS
55	Health Care Reimbursement and Service Utilization Among Medicare Beneficiaries with Multiple Myeloma Receiving Autologous Hematopoietic Cell Transplantation in Inpatient and Outpatient Settings. <i>Blood</i> , 2018, 132, 832-832.	1.4	1
56	Daratumumab, Pomalidomide, and Dexamethasone (DPd) As Salvage Treatment for Relapsed/Refractory Myeloma Eligible for High-Dose Chemotherapy/Autologous Stem Cell Transplantation. <i>Blood</i> , 2018, 132, 5760-5760.	1.4	0
57	PD-1 blockade for relapsed lymphoma post allogeneic hematopoietic cell transplant: high response rate but frequent GVHD. <i>Blood</i> , 2017, 130, 221-228.	1.4	214
58	Evaluation of Performance Status and Hematopoietic Cell Transplantation Specific Comorbidity Index on Unplanned Admission Rates in Patients with Multiple Myeloma Undergoing Outpatient Autologous Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 1641-1645.	2.0	14
59	Effect of Rituximab on Pulmonary Function in Bronchiolitis Obliterans Syndrome due to Graft-Versus-Host-Disease. <i>Lung</i> , 2017, 195, 781-788.	3.3	14
60	Allogeneic Transplantation for Relapsed Waldenström Macroglobulinemia and Lymphoplasmacytic Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 60-66.	2.0	17
61	Maintenance versus Induction Therapy Choice on Outcomes after Autologous Transplantation for Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 269-277.	2.0	19
62	Effect of extracorporeal photopheresis on lung function decline for severe bronchiolitis obliterans syndrome following allogeneic stem cell transplantation. <i>Journal of Clinical Apheresis</i> , 2016, 31, 347-352.	1.3	22
63	Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014.	4.1	45
64	Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. <i>British Journal of Haematology</i> , 2016, 174, 235-248.	2.5	115
65	Reduced-intensity transplantation for lymphomas using haploidentical related donors vs HLA-matched unrelated donors. <i>Blood</i> , 2016, 127, 938-947.	1.4	246
66	Post-Transplant Outcomes in High-Risk Compared with Non-High-Risk Multiple Myeloma: A CIBMTR Analysis. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1893-1899.	2.0	34
67	Tolerability and outcome of once weekly liposomal amphotericin B for the prevention of invasive fungal infections in hematopoietic stem cell transplant patients with graft-versus-host disease. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 228-234.	0.9	11
68	Hematopoietic Cell Transplantation Outcomes in Monosomal Karyotype Myeloid Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 248-257.	2.0	33
69	Adequacy of peripheral blood stem cell mobilization in patients with relapsed B-cell non-Hodgkin lymphoma treated with bendamustine. <i>Leukemia and Lymphoma</i> , 2016, 57, 1189-1190.	1.3	2
70	A pilot study using hyperbaric oxygen therapy to improve umbilical cord blood stem cell engraftment: 6-months follow up results.. <i>Journal of Clinical Oncology</i> , 2016, 34, 7048-7048.	1.6	0
71	Transfusion support and post-transplant complications in autologous transplant patients receiving hyperbaric oxygen.. <i>Journal of Clinical Oncology</i> , 2016, 34, e19004-e19004.	1.6	0
72	Impact of Pretransplantation 18F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1605-1611.	2.0	39

#	ARTICLE	IF	CITATIONS
73	Hematopoietic Stem Cell Transplantation for Multiple Myeloma: Guidelines from the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1155-1166.	2.0	104
74	Reduced-Intensity Allografting as First Transplantation Approach in Relapsed/Refractory Grades One and Two Follicular Lymphoma Provides Improved Outcomes in Long-Term Survivors. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 2091-2099.	2.0	55
75	Routine radiographic screening after completion of initial chemotherapy and relapse-free survival after transplant in patients with relapsed lymphoma. <i>Leukemia and Lymphoma</i> , 2015, 56, 518-519.	1.3	0
76	Outcomes for newly diagnosed patients with acute myeloid leukemia dosed on actual or adjusted body weight. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 691-697.	2.3	6
77	Heat Shock Factor 1 Promotes NF-Kb and B-Cell Signaling in a Preclinical Model of Chronic Lymphocytic Leukemia. <i>Blood</i> , 2015, 126, 5297-5297.	1.4	1
78	The impact of HBO on early ALC recovery following high-dose therapy and autologous transplantation.. <i>Journal of Clinical Oncology</i> , 2015, 33, 7034-7034.	1.6	0
79	Combined use of multiday palonosetron with aprepitant and low-dose dexamethasone in prevention of nausea and emesis among patients with multiple myeloma and lymphoma undergoing autologous hematopoietic stem cell transplant: A pilot study. <i>Journal of Oncology Pharmacy Practice</i> , 2014, 20, 263-269.	0.9	9
80	Complete molecular testing in AML.. <i>Journal of Clinical Oncology</i> , 2014, 32, e18016-e18016.	1.6	0
81	Pilot Clinical Study Incorporating Hyperbaric Oxygen into Umbilical Cord Blood Transplantation. <i>Blood</i> , 2014, 124, 3889-3889.	1.4	0
82	Decitabine in patients with relapsed acute myeloid leukemia (AML) after allogeneic stem cell transplantation (allo-SCT). <i>Annals of Hematology</i> , 2013, 92, 549-550.	1.8	26
83	Outpatient Cytarabine Administration Is Safe and Effective For Consolidation In Acute Myeloid Leukemia. <i>Blood</i> , 2013, 122, 5030-5030.	1.4	6
84	Efficacy and Relative Costs Of Re-Induction Chemotherapy With Clofarabine and Cytarabine For Adults With AML. <i>Blood</i> , 2013, 122, 5043-5043.	1.4	2
85	SAR245409 Monotherapy In Relapsed/Refractory Follicular Lymphoma: Preliminary Results From The Phase II ARD12130 Study. <i>Blood</i> , 2013, 122, 86-86.	1.4	8
86	Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. <i>Clinical Transplantation</i> , 2012, 26, 447-453.	1.6	23
87	Combined targeting of LSD1 (KDM1A) and histone deacetylases exerts superior efficacy against human AML.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10549-10549.	1.6	0
88	Effect of auranofin on oxidative and endoplasmic reticulum stress as well as anti-CLL activity with proteasome inhibitor.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13568-e13568.	1.6	0
89	Anti-AML activity of a novel beta-catenin antagonist BC2059.. <i>Journal of Clinical Oncology</i> , 2012, 30, 10605-10605.	1.6	0
90	Propylene Glycol-Free Melphalan Induces Higher Remission Rates in Multiple Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2012, 120, 4551-4551.	1.4	0



#	ARTICLE	IF	CITATIONS
91	Activity of Allosteric, Switch-Pocket, ABL/FLT3 Kinase Inhibitor DCC2036 Against Cultured and Primary AML Progenitors with FLT-ITD or FLT3 Kinase Domain Mutations. <i>Blood</i> , 2011, 118, 2611-2611.	1.4	2
92	Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells. <i>Blood</i> , 2011, 118, 2429-2429.	1.4	0
93	Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCl for Injection (Propylene Glycol-Free) and Alkeran for Injection for Myeloablative Conditioning in Multiple Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2011, 118, 4512-4512.	1.4	1
94	Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarabine and FLT3 Antagonists. <i>Blood</i> , 2011, 118, 733-733.	1.4	0
95	Treatment with $\beta$ -Catenin Antagonist BC2059 Exerts Single Agent Efficacy and Exerts Improved Activity with Tyrosine Kinase Inhibitor (TKI) or Pan-Histone Deacetylase (HDAC) Inhibitor Against Human CML and Myeloproliferative Neoplasm (MPN) Progenitor Cells. <i>Blood</i> , 2011, 118, 65-65.	1.4	2
96	Treatment with Auranofin Induces Oxidative and Lethal Endoplasmic Reticulum (ER) Stress Exerting Single Agent Activity Against Primary CLL Cells. <i>Blood</i> , 2011, 118, 929-929.	1.4	0
97	Results of a Phase I Open-Label Study of Decitabine in Combination with Midostaurin (PKC412) for Elderly (Age $\geq$ 60) Newly Diagnosed or Relapsed/Refractory Adult Patients with Acute Myeloid Leukemia. <i>Blood</i> , 2011, 118, 3610-3610.	1.4	0
98	Blastic plasmacytoid dendritic cell neoplasm should be treated with acute leukemia type induction chemotherapy and allogeneic stem cell transplantation in first remission. <i>International Journal of Hematology</i> , 2010, 92, 398-400.	1.6	21
99	A Phase IIa, Open-Label, Randomized, Pharmacokinetic Comparative, Cross-Over Study of Melphalan HCl for Injection (propylene glycol-free) and Alkeran for Injection for Myeloablative Conditioning In Multiple Myeloma Patients Undergoing Autologous Transplantation. <i>Blood</i> , 2010, 116, 4525-4525.	1.4	0
100	Combined Use of Multi-Day Doses of Palonosetron and Aprepitant with Low Dose Dexamethasone In Prevention of Nausea and Emesis Among Patients with Multiple Myeloma and Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplant (ASCT): A Pilot Study. <i>Blood</i> , 2010, 116, 1335-1335.	1.4	0
101	Leukemic Phase of Follicular Lymphoma after Treatment with Etanercept in a Patient with Psoriasis. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 125-126.	6.7	12
102	Acute Intracerebral Hemorrhage in Intravascular Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 211-212.	1.3	16
103	Burkitt's Lymphoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2007, 30, 656-657.	1.3	0
104	Is there a plateau in the survival curve after autologous transplantation in patients with intermediate and high-risk acute myeloid leukemia? A 20-year single institution experience. <i>Leukemia Research</i> , 2007, 31, 1253-1257.	0.8	5
105	A Case of Synchronous Lymphoplasmacytic Lymphoma and Rectal Carcinoid. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2006, 29, 104-105.	1.3	4
106	Autologous transplantation in patients with relapsed or high-grade follicular lymphoma provides long term disease-free survival and best median duration of response. <i>Annals of Hematology</i> , 2005, 84, 526-531.	1.8	5
107	Idiopathic thrombocytopenic purpura associated with bone marrow sea-blue histiocytosis. <i>American Journal of Hematology</i> , 2004, 77, 405-406.	4.1	4
108	Outcomes of VDPACE with an immunomodulatory agent as a salvage therapy in relapsed/refractory multiple myeloma with extramedullary disease. <i>EJHaem</i> , 0, , .	1.0	2